MindMed to Participate in September Investor Conferences

9/4/24 7:00:00 AM ET

Medicinal Chemicals and Botanical Products

Health Care

Get the next $MNMD alert in real time by email

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that members of the Company's management team will participate in the following investor conferences:

H.C. Wainwright 26^th Annual Global Investment Conference
- Format: Panel
- Panel Title: Psychedelics in Psychiatry: Breaking New Ground in Mood Disorders
- Date and Time: Tuesday, September 10, 2024 at 3:00 PM ET
- Location: New York, NY
Baird's 2024 Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Wednesday, September 11, 2024 at 12:15 PM ET
- Location: New York, NY
- Webcast Link: Baird's 2024 Global Healthcare Conference
2024 Cantor Global Healthcare Conference
- Format: Fireside Chat
- Date and Time: Tuesday, September, 17 at 10:20 AM ET
- Location: New York, NY
- Webcast Link: 2024 Cantor Global Healthcare Conference

Audio webcasts and replays of available presentations will be accessible on MindMed's Investor Relations website for up to 90 days following each event.

About MindMed

MindMed is a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904981833/en/

Get the next $MNMD alert in real time by email

Recent Analyst Ratings for

$MNMD

Date	Price Target	Rating	Analyst
10/14/2024	$20.00	Outperform	Leerink Partners
7/24/2024	$36.00	Buy	ROTH MKM
5/29/2024	$27.00	Outperform	Robert W. Baird
4/15/2024	$20.00	Outperform	Leerink Partners
12/5/2023	$9.00	Buy	Canaccord Genuity
12/9/2022	$25.00	Buy	ROTH Capital
11/16/2022	$5.00	Outperform	RBC Capital Mkts
8/26/2022	$3.50	Outperform	Oppenheimer

More analyst ratings

MindMed to Participate in September Investor Conferences

Chat with this insight

Recent Analyst Ratings for $MNMD

$MNMD Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners resumed coverage on MindMed with a new price target

ROTH MKM initiated coverage on MindMed with a new price target

Robert W. Baird initiated coverage on MindMed with a new price target

$MNMD Market Insights

Live Market Insights

Roth MKM Maintains Buy on Mind Medicine, Maintains $36 Price Target

MindMed Announces PAtent Covering MM120 Orally Disintegrating Tablet

'MDMA Therapy Gets Support From Prominent Research Group As FDA Weighs Action' - Green Market Report

$MNMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Accounting Officer Liao Carrie sold $14,065 worth of shares (2,352 units at $5.98), decreasing direct ownership by 2% to 99,543 units (SEC Form 4)

Chief Executive Officer Barrow Robert sold $118,231 worth of shares (19,771 units at $5.98), decreasing direct ownership by 3% to 545,772 units (SEC Form 4)

Chief Medical Officer Karlin Dan sold $41,089 worth of shares (6,871 units at $5.98), decreasing direct ownership by 2% to 344,656 units (SEC Form 4)

$MNMD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Gryska David W bought $20,930 worth of shares (3,500 units at $5.98), increasing direct ownership by 25% to 17,351 units (SEC Form 4)

Chief Executive Officer Barrow Robert bought $6,215 worth of shares (1,000 units at $6.21), increasing direct ownership by 0.18% to 565,543 units (SEC Form 4)

$MNMD Press Releases

Fastest customizable press release news feed in the world

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

MindMed to Participate in Upcoming Investor Conferences

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

$MNMD Leadership Updates

Live Leadership Updates

MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer

KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

$MNMD Financials

Live finance-specific insights

MindMed Reports Third Quarter 2024 Financial Results and Business Updates

MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update

MindMed Reports Second Quarter 2024 Financial Results and Business Updates

$MNMD SEC Filings

SEC Form 10-Q filed by Mind Medicine (MindMed) Inc.

Mind Medicine (MindMed) Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 424B3 filed by Mind Medicine (MindMed) Inc.

$MNMD Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Mind Medicine (MindMed) Inc.

SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

SEC Form SC 13G filed by Mind Medicine (MindMed) Inc.

Recent Analyst Ratings for
$MNMD

$MNMD
Analyst Ratings

$MNMD
Market Insights

$MNMD
Insider Trading

$MNMD
Insider Purchases

$MNMD
Press Releases

$MNMD
Leadership Updates

$MNMD
Financials

$MNMD
SEC Filings

$MNMD
Large Ownership Changes